Manfred Koegl

机构：Boehringer Ingelheim (Austria) · ORCID：0000-0001-6633-9769

发表论文 82 篇 · 总被引 7135 次 · h-index 36

代表论文

• BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design (2019 · Nature Chemical Biology · 被引 589)
• Drugging an undruggable pocket on KRAS (2019 · Proceedings of the National Academy of Sciences · 被引 455)
• Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel–Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7 (2018 · Journal of Medicinal Chemistry · 被引 343)
• Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor (2016 · Journal of Medicinal Chemistry · 被引 228)
• A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo (2022 · Nature Communications · 被引 220)
• Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6 (2017 · Cell Reports · 被引 209)